Boston Scientific (BSX) Projected to Post Earnings on Wednesday

Boston Scientific (NYSE:BSX - Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, January 29th. Analysts expect the company to announce earnings of $0.65 per share and revenue of $4,399,115.24 billion for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.50 EPS. On average, analysts expect Boston Scientific to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Price Performance

Shares of BSX traded down $0.62 during mid-day trading on Wednesday, hitting $100.29. The company's stock had a trading volume of 8,170,659 shares, compared to its average volume of 5,732,579. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a 50-day moving average price of $91.45 and a 200 day moving average price of $84.93. Boston Scientific has a fifty-two week low of $59.85 and a fifty-two week high of $101.65. The stock has a market capitalization of $147.81 billion, a price-to-earnings ratio of 82.88, a PEG ratio of 2.59 and a beta of 0.80.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent research reports. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Morgan Stanley boosted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, October 24th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a report on Friday, January 10th. BTIG Research lifted their price target on Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research note on Monday, December 16th. Three research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $97.26.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last three months. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.